Results for: Oppenheimer

Oppenheimer analyst Param Singh initiated coverage on Commvault Systems (CVLT) with an Outperform rating and a $200 price target. The analyst believes Commvault is well-positioned to capitalize on the growing demand for data backup and recovery solutions, driven by factors like the increasing importance of data, data security breaches, and the shift to as-a-service platforms. Singh anticipates strong customer growth, market share gains, and a significant increase in SaaS ARR for Commvault in the coming years.

Acclaimed director Christopher Nolan, fresh off his triumph with ‘Oppenheimer’, is gearing up for his next project, boasting an impressive ensemble cast including Zendaya, Tom Holland, Anne Hathaway, and Matt Damon. While details about the plot remain shrouded in secrecy, the film is set to release in July 2026, promising another captivating cinematic experience from the master storyteller.

Oppenheimer has initiated coverage on Larimar Therapeutics (LRMR), a clinical-stage biotech company developing treatments for rare diseases, with an Outperform rating and a $26 price target. The analysts believe Larimar’s lead program, Nomlabofusp, could become a significant treatment option for Friedreich’s ataxia (FA), a rare neurodegenerative disease, due to its potential disease-modifying properties. Oppenheimer expects interim data from an open-label extension (OLE) trial in the fourth quarter of 2024 and anticipates a potential FDA marketing application submission in the second half of 2025.

Oppenheimer analyst has increased the price target for Uber Technologies, citing strong potential for restaurant delivery growth. The analyst’s survey reveals significant opportunity for new user acquisition through better marketing. Despite economic pressures, the analyst expects Uber Delivery gross transaction value to rise due to increased frequency and anticipated consumer tailwinds from expected rate cuts in 2025.

Corbus Pharmaceuticals (CRBP) has received reaffirmed Buy ratings from both H.C. Wainwright and Oppenheimer despite a recent stock decline triggered by disappointing data from Novo Nordisk’s obesity drug. Analysts remain optimistic about Corbus’ diverse pipeline, highlighting the potential of its CRB-913 and CRB-701.

Amazon Prime Video is kicking off the summer season with a lineup that includes the highly anticipated fourth season of “The Boys,” as well as last year’s Oscar winner for Best Picture, “Oppenheimer.” Additionally, the Mean Girls musical remake and the documentary “Federer: Twelve Final Days” will be making their way to the streaming service. For those looking to binge-watch, the drama series “Las Vegas” will be available on Prime Video starting June 1st.

Despite challenges faced by the gaming industry, Oppenheimer remains optimistic about Electronic Arts’ prospects, maintaining its Outperform rating and $150.00 price target. While acknowledging recent underperformance of ‘Apex Legends’ and moderating fiscal year 2025 forecasts, the firm suggests potential catalysts in the latter half of 2024 that could make Electronic Arts an attractive investment compared to its peer Take-Two Interactive. Oppenheimer’s analysis points to the company’s strong market position, portfolio of popular gaming franchises, and strategic positioning as key factors driving its positive outlook.